Target intelligence / Profile preview

Isobutyryl-CoA dehydrogenase, mitochondrial (ACAD8)

Target
ACAD8
Molecular classification
Enzyme, Acyl-CoA dehydrogenase family, Mitochondrial protein
01

Overview

Isobutyryl-CoA dehydrogenase, mitochondrial (encoded by the ACAD8 gene), is an enzyme of the acyl-CoA dehydrogenase family that catalyzes the dehydrogenation of isobutyryl-CoA in the catabolic pathway of the branched-chain amino acid valine[1][2][3][4]. The protein is localized in mitochondria and plays a central role in intermediary metabolism—specifically in converting isobutyryl-CoA to methacryloyl-CoA at the third step of valine breakdown. Mutations in the ACAD8 gene cause isobutyryl-CoA dehydrogenase deficiency, a rare autosomal recessive disorder often detected by elevated C4-acylcarnitine in newborn blood screening. The clinical phenotype is highly variable: most individuals show no symptoms, but some exhibit mild growth/developmental delay, hepatic dysfunction, cold intolerance, or in rare cases, cardiomyopathy. ACAD8 deficiency is typically managed by metabolic monitoring and, if symptomatic, dietary intervention[1][2][3][4].

Other names
Isobutyryl-CoA dehydrogenase, mitochondrialACAD8ACAD-8ARC42IBDIBDHactivator-recruited cofactor 42 kDa componentacyl-CoA dehydrogenase family member 8
02

Mechanism of action

Not applicable (no known drugs targeting ACAD8 directly). - Enzyme deficiency: therapeutic approaches may involve dietary management and monitoring, not targeted drugs.

03

Biological functions

Catabolism of branched-chain amino acids (notably valine)Fatty acid metabolismCatalysis of dehydrogenation of isobutyryl-CoA to methacryloyl-CoAIntermediary metabolism
04

Disease associations

Inborn error of metabolism (Isobutyryl-CoA dehydrogenase deficiency, IBDD)Possible association with hepatic steatosis, cold intolerance, developmental delay, dilated cardiomyopathy (rare, sporadic reports)
05

Safety considerations

Diagnosis is complicated by variable penetrance (many carriers asymptomatic)Overlapping biochemical markers with other metabolic disorders can complicate diagnosisAccumulation of toxic metabolic intermediates if untreated
06

Interacting drugs

None documented in current literature or drug databases specifically interacting with ACAD8 as a pharmacological target[1][2][3][4]
07

Biomarkers

Elevated C4-acylcarnitine in blood (newborn screening)Increased isobutyrylglycine in urineElevated 3-hydroxypropionic acid (in some cases)

Beyond the preview

Go deeper on Isobutyryl-CoA dehydrogenase, mitochondrial (ACAD8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Isobutyryl-CoA dehydrogenase, mitochondrial (ACAD8).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call